Treatment of osteoporosis in elderly women
- PMID: 7709938
Treatment of osteoporosis in elderly women
Abstract
Prevention of osteoporosis is better than cure. This intuitive wisdom is strengthened by knowledge that osteoporosis due to gonadal deficiency is associated with a disruption of skeletal architecture that is irreversible by current treatments. Moreover, it is commonly assumed that bone is lost more slowly in later life than in the several years after the menopause, so that factors other than decreasing bone mass are assumed to be of greater importance for fracture risk. With the exception of fluoride, current treatments have not been shown to restore skeletal mass in patients with osteoporosis. These views have suggested that the management of osteoporosis in the elderly is of limited value and have reinforced the importance of preventive measures. Notwithstanding, there are several reasons for believing that intervention late in the natural history of bone loss is worthwhile. Whereas cross-sectional studies suggest that bone loss declines in later years, prospective studies indicate that bone loss is progressive and indeed accelerates in extreme old age. Moreover, the measurement of bone mass predicts future fracture in the elderly as effectively as it does at the time of the menopause. There are also several reasons why preventive approaches at the time of the menopause have limited applicability. Since current preventive treatments cannot be given indefinitely, a crucial question concerns the extent to which reversal of effect occurs after treatment withdrawal. If catch-up bone loss does occur, it decreases markedly the cost-effectiveness of therapeutic intervention at the menopause and provides a convincing rationale for the use of interventions at a much later age. The optimum age for starting treatment is not yet determined but might be best directed 15 or so years after the menopause, well before the mean age of hip fracture. Since hip fracture provides the greatest socioeconomic impact of osteoporosis and since evidence is accumulating that treatments favorably affect hip fracture risk, it is suggested that greater attention should be given to the management of osteoporosis in the elderly.
Similar articles
-
Why elderly women should be screened and treated to prevent osteoporosis.Am J Med. 1995 Feb 27;98(2A):67S-75S. doi: 10.1016/s0002-9343(05)80050-6. Am J Med. 1995. PMID: 7709939 Review.
-
Bisphosphonates for prevention of postmenopausal osteoporosis.Dan Med Bull. 2002 Feb;49(1):1-18. Dan Med Bull. 2002. PMID: 11894721 Review.
-
Osteoporosis-an update.JNMA J Nepal Med Assoc. 2005 Apr-Jun;44(158):60-6. JNMA J Nepal Med Assoc. 2005. PMID: 16568580 Review.
-
Osteoporosis: preventive strategies.Int J Fertil Womens Med. 1998 Mar-Apr;43(2):56-64. Int J Fertil Womens Med. 1998. PMID: 9609204 Review.
-
Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study.J Bone Miner Res. 2004 Apr;19(4):532-6. doi: 10.1359/JBMR.040109. Epub 2004 Jan 5. J Bone Miner Res. 2004. PMID: 15005838
Cited by
-
Risk for osteoporosis in black women.Calcif Tissue Int. 1996 Dec;59(6):415-23. doi: 10.1007/BF00369203. Calcif Tissue Int. 1996. PMID: 8939764
-
Classification of osteoporosis in the elderly is dependent on site-specific analysis.Calcif Tissue Int. 1996 Jun;58(6):409-14. doi: 10.1007/BF02509439. Calcif Tissue Int. 1996. PMID: 8661481
-
Anti-osteoporotic effects of Pueraria candollei var. mirifica on bone mineral density and histomorphometry in estrogen-deficient rats.J Nat Med. 2016 Apr;70(2):225-33. doi: 10.1007/s11418-016-0965-5. Epub 2016 Jan 27. J Nat Med. 2016. PMID: 26815435
-
Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women.Eur J Nucl Med. 1996 Nov;23(11):1473-7. doi: 10.1007/BF01254471. Eur J Nucl Med. 1996. PMID: 8854845
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources